Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

The use of the compound

A technology of compounds and uses, applied in the field of pharmaceutical use of compounds, to achieve the effects of inhibiting migration, good anti-angiogenic activity, and promoting cell apoptosis

Active Publication Date: 2020-12-08
BEIJING UNIV OF CHINESE MEDICINE
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0007] The compound represented by the formula (I) shown below is a chemical component isolated from Dracaena japonicus, but no reports about its pharmacological activity have been seen yet:

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • The use of the compound
  • The use of the compound
  • The use of the compound

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0039] Embodiment 1-cell proliferation experiment

[0040] experimental method:

[0041] HepG2 and SKHEP-1 cells in the logarithmic growth phase were taken, and cell suspensions were prepared respectively, and the number of cells was adjusted to 3.5×10 4 A / mL~4.0×10 4cells / mL, added to 96-well plate, 100 μl per well. The cells were cultured for 24 hours to make them completely adhere to the wall, and the mother solution of the compound represented by formula (I) was diluted with complete medium into working solutions of different concentrations, and 5 replicate wells were set for each concentration. After 24 hours, 48 ​​hours, and 72 hours after the addition of the drug, the original medium in the well plate was precipitated, and the 5mg / ml MTT reagent was prepared into a 10% concentration with the basal medium and added to the 96-well plate. The plate was incubated in a floating chamber at 37°C for 4 hours, then taken out, and 150 μl of DMSO was added to each well, disso...

Embodiment 2

[0046] Embodiment 2-apoptosis experiment

[0047] experimental method:

[0048] (1) Hoechst staining method: Take HepG2 and SKHEP-1 cells in the logarithmic growth phase, pipette them into a single cell suspension with complete medium, inoculate them in a 12-well plate, and culture them in an incubator for 24 hours to make them adhere to the wall Add different concentrations of compounds represented by formula (I) and incubate for 48 hours, wash twice with PBS, fix with 4% paraformaldehyde for 10 minutes, and stain with Hoechst 33258 dye solution with a final concentration of 1 μg / ml in the dark for 30 minutes, place Under an inverted fluorescent microscope, observe and take pictures. Experiments were repeated at least three times independently.

[0049] (2) Flow cytometry assay: HepG2 and SKHEP-1 cells were inoculated in 6-well plates at a concentration of 1×105 / mL, and after overnight attachment, the final concentrations of 0, 5, 10, and 15 μM were added to the formula (...

Embodiment 3

[0055] Embodiment 3-cell scratch experiment

[0056] experimental method:

[0057] HepG2 and SKHEP-1 cells were seeded in 12-well plates, and when the cells were in a subconfluent state, they were starved for 12 hours with serum-free DMEM high-sugar medium. Use a 10 μl white pipette tip to scratch vertically and gently with even force. 1×PBS was used to wash the cell debris floating due to scratching, at least 3 times. Take pictures as a blank control before dosing. Dilute the mother solution of the compound represented by formula (I) into working solutions of 0, 2, 4 and 8 μM with serum-free basal medium, add drugs to stimulate the cells respectively, observe and take pictures under a phase contrast microscope 12 hours and 24 hours after scratching, and evaluate The size of the cell migration ability.

[0058] Experimental results:

[0059] The cell scratch test was used to evaluate the migration ability of cells in vitro. The effects of different concentrations of co...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a compound, a prodrug thereof or use of a medicinal salt of the compound in preparing an anti-tumor drug. The compound has the following structure (described in the following description).

Description

technical field [0001] The present invention relates to a pharmaceutical application of a compound. Background technique [0002] In recent years, with the intensification of environmental pollution, the increase of people's work pressure and the escalation of food safety problems, the incidence of malignant tumors has risen, and cancer has become the number one killer threatening human health. question. [0003] In recent years, studies have shown that finding new antitumor drugs from natural products has broad prospects and great potential. Dracaena dracaena is the resin of the Liliaceae sword-leaf dracaena. It is mainly distributed in Yunnan, my country and Southeast Asian countries. It has various physiological and pharmacological effects such as promoting blood circulation and removing blood stasis, anti-inflammatory pain relief, promoting muscle regeneration, and immune regulation. It is mainly used in heart disease. Vascular diseases, digestive system diseases, diabe...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K31/353A61P35/00
CPCA61K31/353A61P35/00
Inventor 屠鹏飞胡仲冬李军赵亚楠杨爱琳庞道然苏小琴
Owner BEIJING UNIV OF CHINESE MEDICINE
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com